PSY1 Cardiovascular and Congenital Safety Evaluation of Antiobesity Agents, Including Topiramate- A Pharmacovigilance Analysis of the Adverse Event Reporting System
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1724
https://www.valueinhealthjournal.com/article/S1098-3015(12)03437-7/fulltext
Title :
PSY1 Cardiovascular and Congenital Safety Evaluation of Antiobesity Agents, Including Topiramate- A Pharmacovigilance Analysis of the Adverse Event Reporting System
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03437-7&doi=10.1016/j.jval.2012.08.1724
First page :
A508
Section Title :
Systemic Disorders/Conditions
Open access? :
No
Section Order :
1217